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Background: Austism spectrum disorder (ASD) is a heterogeneous behavioral disorder or condition characterized
by severe impairment of social engagement and the presence of repetitive activities. The molecular etiology of ASD
is still largely unknown despite a strong genetic component. Part of the difficulty in turning genetics into disease
mechanisms and potentially new therapeutics is the sheer number and diversity of the genes that have been
associated with ASD and ASD symptoms. The goal of this work is to use shRNA-generated models of genetic
defects proposed as causative for ASD to identify the common pathways that might explain how they produce a
core clinical disability.
Methods: Transcript levels of Mecp2, Mef2a, Mef2d, Fmr1, Nlgn1, Nlgn3, Pten, and Shank3 were knocked-down in
mouse primary neuron cultures using shRNA constructs. Whole genome expression analysis was conducted for each
of the knockdown cultures as well as a mock-transduced culture and a culture exposed to a lentivirus expressing an
anti-luciferase shRNA. Gene set enrichment and a causal reasoning engine was employed to identify pathway level
perturbations generated by the transcript knockdown.
Results: Quantification of the shRNA targets confirmed the successful knockdown at the transcript and protein
levels of at least 75% for each of the genes. After subtracting out potential artifacts caused by viral infection, gene
set enrichment and causal reasoning engine analysis showed that a significant number of gene expression changes
mapped to pathways associated with neurogenesis, long-term potentiation, and synaptic activity.
Conclusions: This work demonstrates that despite the complex genetic nature of ASD, there are common
molecular mechanisms that connect many of the best established autism candidate genes. By identifying the key
regulatory checkpoints in the interlinking transcriptional networks underlying autism, we are better able to discover
the ideal points of intervention that provide the broadest efficacy across the diverse population of autism patients.Background
Autism spectrum disorder (ASD) is a heterogeneous
developmental disease that is primarily characterized by
behavioral and social impairments such as the presence
of repetitive or ritualistic activities, social withdrawal,
and difficulty with proper communication. ASD is more
commonly diagnosed in male individuals at a 4:1 ratio
and its incidence has notably risen over time. It is
currently estimated that ASD afflicts up to one out of* Correspondence: Mathew.Pletcher@pfizer.com
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reproduction in any medium, provided the orevery eighty-eight individuals and is now counted as the
second most common developmental disability after
intellectual disability [1-3]. Current treatment options
for autism are limited, focusing primarily on behavioral
therapies and repurposed drugs whose primary indication
is not autism.
It is long been appreciated that ASD has a strong
genetic component underlying its etiology. Early twin
studies, examining the co-inheritance of ASD among
monozygotic twins, reported a heritability rate for ASD
between 60% and 90% [4]. The role of genetics in ASD
has been further elucidated and refined at the single
gene level as tools such as genome-wide associationd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and whole exome/genome sequencing have been applied
to the disease [5-10]. A clear association has been
demonstrated between genetic variants in genes, such
as Contactin-associated protein-like 2 (Cntnap2) and
Semaphorin-5A (Sema5A), and ASD, and the localization
of rare deletions and duplications has not only led to
the identification of new autism candidate genes,
such as SH3 and multiple ankyrin repeat domains 3
(Shank3), but also the creation of new mouse models
that parallel ASD at both the genetic and behavioral
level [11-14].
Our understanding of the genetics and molecular
mechanisms of ASD has also been greatly enriched by
the study of rare diseases caused by mutations in a
well-defined single gene with symptomatic overlap
with ASD. Two of the best known examples of this
are Fragile X and Rett syndromes. Fragile X is caused
by an expansion of a CGG repeat in the Fragile X
mental retardation-1 (Fmr1) gene and results in mental
retardation. Fragile X, because it is X-linked, is preferentially
found in male individuals and 25% to 33% of Fragile X
patients also meet the criteria for ASD, making it one of
the most common genetic causes of autism [15]. Rett
Syndrome is also X-linked but unlike Fragile X and
ASD, it is predominantly diagnosed in female individuals,
because the hemizygous state is often lethal. Rett syndrome
too is marked by mental retardation and frequent comor-
bidity with autism. In addition to being directly tied to
ASD through Rett, Methyl-CpG binding protein 2 (Mecp2),
a transcription factor mutated in Rett, regulates the expres-
sion of other genes that have been tied to ASD, including
Brain-derived neurotrophic factor (Bdnf) [16,17].
Through the use of modern genetic methods and the
study of syndromic forms of autism, over 200 genes have
been associated with ASD [18]. In an attempt to gain a
better understanding of molecular pathophysiology of
the disease, tools such as pathway analysis [19] and
protein-protein interaction networks [20-22] have been
deployed to identify common mechanisms among these
autism-risk genes, and one of the dominant themes that
has emerged is a convergence on synapse integrity and
dendritic spine formation [23-25]. Phosphatase and
tensin homolog (Pten), the causative gene for Cowden
syndrome - another syndromic form of autism - is shown
to cause increased neuronal spine density, dysfunction in
excitatory and inhibitory synaptic activity and decreased
synaptic plasticity when deleted [26-28]. Shank3 encodes a
synaptic scaffolding protein while Neuroligin 1 and 3
(Nlgn1, Nlgn3) produce synaptic cellular adhesion
molecules. All three genes have been shown to be altered
in ASD patients [29-31]. Finally, Myocyte enhancer factor
2A and 2D (Mef2A, Mef2D) are activity-dependent genes
that encode transcription factors regulating multipleadditional genes implicated in ASD (Ube3A, Slc9A6,
Pcdh10, and C3orf58) [32], and knockdown of these
genes in primary neurons has been shown to regulate
synapse density [33].
Despite the clues that have been provided by these
genetic links, a true understanding of how those genetic
defects translate into altered biology have continued to
be elusive and therefore have made the development of
new therapies for ASD difficult. The current gross
appreciation of impacted dendritic spines and synaptic
health falls short of the digital visualization of the
molecular mechanisms of ASD necessary to advance the
field. Therefore, in this study, we sought to determine
the molecular consequences of the loss of function of
these diverse genes that have been genetically implicated
in autism by use of an in vitro model system. Primary
neuronal cultures are a well-established model for studying
fundamental synaptic biology with a well-characterized
trajectory of synaptic differentiation and function [5,34].
These cultures have proven to be a robust system for
characterizing the transcriptional consequences of synaptic
modulation under a number of settings [32,35,36]. We have
focused on cortex as a tissue of origin based on observation
of pathologic changes in post-mortem ASD cortex [8] and
prior work studying ASD-relevant gene function in cortical
neurons [10].
By knocking down Mecp2, Mef2a, Mef2d, Fmr1,
Nlgn1, Nlgn3, Pten, and Shank3 (Table 1) in murine
primary cortical neurons, we were able to compare and
contrast the varying transcriptional profiles of each
transcriptional inhibition to arrive at core signaling
pathways that unite this otherwise disparate group.
Pathways that are in common between the various
candidate genes would provide one potential explanation
of how a mutation in each them might produce the same
clinical outcome - ASD. As all of these genes play a role
relevant for synaptic structure or function, the hypothesis
was that common downstream genes and pathways might
be perturbed. For a disorder with heterogeneous genetic
backgrounds that produce common behavioral phenotypes,
a common molecular pathway could provide a new avenue
for therapeutic intervention.
Methods
Lentiviral shRNA construct generation and production
Lentiviral constructs were generated by cloning annealed
and kinased, complementary oligonucleotides into the
lentiviral vector pLL3.7_H1 (a version of pLL3.7, Patrick
Stern-MIT, modified to encode human H1 promoter to
drive short-hairpin (sh)RNA expression). Individual gene’s
target sense sequence (Table 2) followed by the loop
sequence TTCAAGAGA, targets’ corresponding anti-
sense and TTTTTT terminator sequences oligos were
ligated (New England Biolabs, Ipswich, MA, USA) into




Methyl CpG binding protein 2 (Mecp2) Transcriptional repressor Nuclear Causes Rett syndrome, which shares some




Transcription factor Nuclear Rare single gene mutation in downstream targets




Transcription factor Nuclear Rare single gene mutation in downstream targets
associated with Autism symptom domains
[32]
Fragile X mental retardation 1 (Fmr1) RNA binding protein Nuclear Causes Fragile X, which shares some symptom
domains with autism
[38]
Neuroligin-1 (Nlgn1) Synaptic remodeling Synaptic Rare single gene mutation associated with
autism symptom domains
[30]
Neuroligin-3 (Nlgn3) Synaptic remodeling Synaptic Rare single gene mutation associated with
autism symptom domains
[31]
Phosphatase and tensin homolog (Pten) Regulator of the
cell cycle
Nuclear and synaptic Causes Cowden syndrome which shares some
symptom domains with autism
[26,39]
SH3 and multiple ankyrin repeat
domains 3 (Shank3)
Scaffold protein Synaptic Rare single gene mutation associated with
autism symptom domains
[12,29]
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the human H1 promoter into pLL3.7_H1.
Lentivirus was produced per manufacturer’s instruc-
tions via quadruple co-transfection of shRNA-containing
pLL3.7_H1 plasmid along with the 3 plasmid ViraPower
(Life Technologies, Grand Island, NY, USA) system into
HEK293T cells. Then, 24 hours post transfection, the
media were changed to complete neurobasal media
(Life Technologies) and lentivirus-conditioned media were
harvested 48 hours later. Functional titer was determined
based on green fluorescent protein (GFP) co-expression in
HEK293T cells using flow cytometry (FACscalibur, Becton
Dickenson, Franklin Lakes, NJ, USA). Optimal lentiviral
transduction of primary cultured cortical neurons was
determined to be a multiplicity of infection (MOI) of 3.0,
based on fluorescence.
Primary neuronal cultures and transductions
Mouse primary neuronal cultures were prepared from
day-16 C57BL6/J embryos. All procedures related toTable 2 shRNA sequences used for knockdown experiments









Luciferase (pGL3-Basic) U47295animal care and treatment were conducted under a
protocol approved by the Pfizer Institutional Animal Care
and Use Committee, according to the guidelines of the
National Research Council Institute for Laboratory Animal
Research Guide for the Care and Use of Laboratory
Animals and the US Department of Agriculture Animal
Welfare Act and Animal Welfare Regulations. Briefly,
timed pregnant dams were received from Jackson
Laboratories and whole brains were removed and
plated into Hank’s (Life Technologies) solution for
dissection (10uM of MgCl2; 7uM of HEPES; 2 mM
glutamine; 100ug/mL penicillin, 100U/mL streptomycin
were also added). Cortex was then cut and dissociated
by a 10-minute trypsin treatment. Then, 500,000 cor-
tical cells were placed on 6-well Poly-D-Lysine-coated
tissue culture plates and maintained in serum-free
medium (medium component: neurobasal medium
(Life Technologies) containing 1X B27 supplement
(Life Technologies), 2 mM glutamine, 100ug/mL penicillin,
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transduced at 2 days in vitro (DIV2) at an optimized
MOI of 3.0. Lentiviral particles remained for 6 hours,
after which, particles were removed and replaced with
conditioned complete neurobasal medium. Cultures
were allowed to mature for an additional 14 days post
transduction (DIV16), at which time, total RNA was isolated
(described below).
Hairpin validation
For each gene target, five unique shRNA targeting
lentiviral constructs were generated as described above,
along with an shRNA control (designed against luciferase),
and used to produce small-scale lentiviral stocks. Viral
stocks were used to transduce primary cortical neuronal
cultures (see primary neuronal cultures and transduction
methods) on DIV2 and cells were grown in culture an
additional 7 to 10 days. Total RNA and protein were
isolated from replicate cultures. Quantitative PCR (qPCR)
(Figure 1) and western blot (Additional file 1: Figure S1)
was performed to validate a minimum knockdown level of
75% at the mRNA (described below) and protein levels for
all hairpin constructs used in study. Glyceraldehyde
3-phosphate dehydrogenase (Gapdh) levels were moni-
tored at both the RNA and protein levels as a control. The
best-performing hairpin for each gene was carried forward
for genome-wide expression analysis.
RNA isolation, cDNA synthesis and qPCR
Total RNA was isolated utilizing the Qiagen (Germantown,
MD, USA) RNeasy mini total RNA isolation kit according
to manufacturer’s instructions. RNA quality was validatedFigure 1 shRNA efficiently knocks down RNA levels of target genes. T
RNA-treated neuronal samples are the average values of all target genes. T
Luciferase shRNA-treated cells for any of the targeted genes.utilizing a NanoDrop spectrophotometer (Thermo Fisher
Scientific, Waltham, MA, USA), assuring at least a
2.0 260/280 ratio was obtained. cDNA was generated
from 1 ug total RNA using the Life Technologies High
Capacity RNA-to-cDNA kit (number 4390716) according
to manufacturer’s instructions. Prior to the Affymetrix
(Santa Clara, CA, USA) Gene Chip analysis, qPCR for the
target gene was performed on quadruplicate replicates 15
ngs RNA-equivalent cDNA to ensure knockdown. Only
samples showing acceptable knockdown (>75% knockdown
by mRNA) were submitted for gene chip analysis.
Microarray hybridization and quality control analysis
Total RNA was hybridized to Affymetrix Mouse 430_2
microarrays at Gene Logic (Gaithersburg, MD, USA).
RNA degradation plots were analyzed for quality control
purposes. Four samples did not pass quality control (QC)
and were omitted from further analysis (one each from
the Mef2d, Nlgn1, Shank3, and non-transduced groups).
The raw data files were then normalized using robust
multi-array averaging (RMA) [40]. Hierarchical clustering
by positive correlation (Ward linkage) was performed in
Genedata Expressionist. Prior to statistical analysis, probe
sets with _x designations were excluded for potential
lack of specificity. Additional probe sets were excluded if
absolute expression was <50 for all samples (expression
was considered absent), resulting in 24,343 probe sets for
statistical analysis. Gene expression for all sample types
was analyzed on the log2 scale. Linear models were used
to calculate P-values between the groups of interest. The
linear model t-statistics were regularized using the
moderated-t approach of Smyth [41]. Adjustment ofhe bars representing the Luciferase-targeting control short-hairpin (sh)
here was no significant difference between the untreated cells and
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Hochberg [42] to control for multiplicity of testing.
Each set of microarrays from a shRNA experiment
treatment group were compared to the set of microarrays
from the luciferase shRNA control set. Probe sets with false
discovery rate (FDR)-corrected P-value ≤0.05 and ≥1.5-fold
change were identified for each treatment group for
pathway analysis, as the historic RT-PCR confirmation
rate of microarray data fitting these criteria is approximately
70% (Additional file 2: Table S1). Overlap with a recently
published autism gene interactome [20] was performed for
all treatment groups. All primary microarray data from this
experiment are available in the Gene Expression Omnibus
[GEO:GSE47150].
Bioinformatics analysis of gene expression data
Analyses of gene lists from the miRNA experiments were
performed using either Nextbio™ software (Santa Clara,
CA, USA, www.nextbio.com), Gene Sensor Suite (GSS), or
the causal reasoning engine (CRE). The NextBio software
uses a modified form of the gene set enrichment algorithm
to identify important pathways and other ontologies [43].
All analyses done with NextBio were done utilizing the
default parameters. NextBio pathway analysis utilized the
pathways compiled by the Broad Institutes gene set enrich-
ment analysis (GSEA) application as part of their molecular
signatures database, MSigDB [44]. Related tissues were
identified from NextBio’s transcriptional profiles for over
6,000 publically available studies. The GSS application
identifies significantly enriched pathways using Fisher’s
exact test and corrected for multiple testing using Q-value
[45,46]. GSS pathways were generated from Ingenuity
pathways from October 2010 (Ingenuity® Systems
(Redwood City, CA, USA), www.ingenuity.com). The CRE
algorithm uses multiple statistical parameters to assess the
similarity to upstream effectors and their downstream
responses to interpret measured gene expression changes
[47,48]. Simply stated, the CRE can be thought of as an
enhanced type of gene set enrichment analysis (GSEA).
Causal statements were curated from the biomedical
literature (Ingenuity and Selventa knowledge bases) in the
form of, X (increases or decreases) Y, such that X and Y
are measured biological quantities. These quantities can
consist of multiple types, including protein modifications,
mRNA levels, biological processes and/or chemical
compound treatments. The combined knowledge base
is then interrogated with the microarray transcriptomic
data to infer upstream events (called hypotheses). The CRE
algorithm generates statistical stringency by employing
two primary methods. First, enrichment of all possible
transcripts for the hypothesis is measured, a method
shared in common with GSS and GSEA. Second, the
method of correctness of the hypothesis is calculated,
and is simply the difference of having the correctdirection minus the incorrect transcripts observed. There
are two advantages in using these methods in the CRE. The
first advantage is that it is a specific molecular interaction of
the hypothesis that is being evaluated. Second, the direc-
tionality of the interaction within the hypothesis is retained
by using the correctness parameter. P-values were generated
and cutoffs were applied using the following filters: correct-
ness P-value <0.05, enrichment P-value <0.05, minimum
number of correctly explained gene expression changes ≥3,
percent correctly explained gene expression changes ≥60%,
ranking score <100. The hypotheses were deciphered and
visualized using the Causal Reasoning Browser, a Java-based
plugin for the open source biomolecular interaction viewer
Cytoscape (www.cytoscape.org)[49].
BDNF quantitation
Neurons were treated in 24-well plates with blank media
or shRNA against luciferase, Fmr1, or Mecp2 in random-
ized wells across two plates (n = 12 per condition). For
protein analysis, neurons were lysed in 20 mM TrisHCl
(pH 7), 137 mM NaCl, 1% NP40, 10% glycerol, 1 mM
PMSF, 10 μg/mL aprotinin, 1 μg/mL leupeptin, and 0.5
mM sodium orthovanadate. Lysates were centrifuged at
14,000 × g for 30 minutes at 4°C. Supernatants were stored
at −80°C until assay. BDNF levels were measured using a
modified version of the Promega (Madison, WI, USA)
BDNF Emax® Immunoassay system (G7611). Half-volume
96-well ELISA plates (Costar®; Corning, Lowell, MA, USA)
were coated with 50 μl anti-BDNF mAb at 1:1000 dilution
in 0.025 M sodium bicarbonate and 0.025 M sodium
carbonate, sealed, and stored at 4°C overnight. Plates were
washed four times with PBS containing 0.05% Tween20,
then blocked for 2 hours at room temperature with
130 μl/well Promega blocking buffer (G3311). Samples
and standards were prepared in blocking buffer (1:4 dilution),
then loaded onto the plates (50 μl) following a wash step.
Plates were sealed and stored at 4 °C. On the third day plates
were washed and incubated with 50 μl/well anti-human
BDNF pAb at 1:500 dilution in blocking buffer for 2 hours at
room temperature. Plates were washed again and
incubated with 50 μl anti-IgY horseradish peroxidase
conjugate at 1:200 dilution in blocking buffer for 1 hour at
room temperature. Following a final wash, 50 μl TMB
solution was added to each well. The reaction was
stopped with 1 N HCl after 10 minutes, and 450 nm
optical densities were read on a Spectramax plate
reader (Molecular Devices, Sunnyvale, CA, USA). Samples
were interpolated off of a standard curve fit by a fourth
order polynomial equation. Interpolated BDNF levels were
normalized to total protein (DC Protein Assay Kit II,
Bio-Rad, Hercules, CA, USA). GraphPad Prism 5.0
was used to perform the Kruskal-Wallis test followed
by the Dunn test for multiple comparisons, to determine
statistically significant changes (P-value <0.05).
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Confirmation of knockdown
Prior to transcriptomic analysis, individual RNA samples
were confirmed for relative knockdown by quantitative
RT-PCR. Average knockdown of replicate samples (Figure 1)
for the candidate genes were as follows: Mecp2 (86%),
Mef2a (94%),Mef2d (89%), Fmr1 (86%), Nlgn1 (89%), Nlgn3
(89%), Pten (95%) and Shank3 (90%). Knockdown was nor-
malized to a single untransduced cortical neuronal sample
(detected message levels were relative to Gapdh). All
individual samples showed at least a 75% knockdown of
target gene expression providing high confidence that the
pathways under investigation were being significantly per-
turbed. Additional experiments (Additional file 1: Figure S1)
indicated that protein levels for all gene products were
decreased in conjunction with lentiviral-mediated RNA
knockdown in the primary neurons.
Evaluation of differentially expressed genes
Expression values for each of the shRNA-targeted genes as
determined by the Affymetrix GeneChips correlated well
with values determined by RT-PCR (Figure 1 - Affymetrix
data from shRNA-treated samples were compared to the
untransfected control for purposes of the figure). Hierarch-
ical clustering of normalized data revealed tight correlation
among biological replicates, with the exception of Mef2a, in
which one sample was separated from the rest (Figure 2).
Pten was the most distinct treatment group, lying in its own
branch of the tree. The next most isolated treatment group
was with Mecp2 knockdown (Additional file 3: Table S2).
These treatments produced the most numerous changes in
gene expression amongst all the hairpins. The total number
of probe sets identified as significantly different from the
luciferase control (>1.5 fold at P <0.05) in each condition
were as follows: Fmr1 (2,395), Mef2d (2,736), Mef2a (1,059),
Mecp2 (3,967), Nlgn1 (1,230), Nlgn3 (2,224), Pten (3,653),
and Shank3 (1,445). Comparison of the luciferase shRNA
versus the untransduced control revealed the smallest
number of significant changes - 997. As an early determin-
ation of the relevance of cell-culture knockdown to the
known molecular biology of ASD, the current datasets were
evaluated for enrichment in an ASD gene interactome
established by Sakai et al. [20]. Although the luciferase
versus blank condition was not significantly enriched for
genes in this interactome, Fmr1, Mecp2, Mef2a, Mef2d,
Nlgn1, Pten, and Shank3 shRNA transcriptomes all
showed significant overlap (Table 3). The most frequently
identified ASD interactome gene was CAMK2A, which
was upregulated by Fmr1 shRNA, but downregulated by
all of the other ASD gene shRNA targets.
NextBio detection of related transcriptional profiles
The Nextbio database allows for comparison of transcrip-
tional profiles between datasets and transcriptional profilesfor over 6,000 publically available studies. The most highly
correlated datasets for any of the ASD gene shRNA profiles
were other ASD shRNA profiles from this experiment. As a
control, the Mef2a and Mef2d profiles were compared
against a published study in which the same hippocampal
neurons were transduced with both Mef2a and Mef2d [32].
The published study showed significant positive correlation
with the present Mef2a and Mef2d datasets, with 107 genes
in common with Mef2a profile and 283 genes in common
with the Mef2d. Similarly, a comparison with microarray
analysis of cortex from Mecp2 knockout mice showed
significant overlap with this Mecp2 shRNA transcriptional
profile (445 genes in common, P = 1 × 10-8) [6]. The most
highly correlated publically available transcriptional profiles
for the remaining ASD-related genes came from compari-
sons of mouse brains at various postnatal ages to embry-
onic day 14.5 [50] or up to birth [51]. A time course of
primary mouse hippocampal neurons in vitro [52] was also
correlated with all shRNA treatments (data not shown). All
of these developmental datasets showed significant inverse
correlation with all shRNA treatments, including luciferase.
Given the number of activity-dependent genes affected by
shRNA treatment, the correlations with developmental
datasets suggest that lentiviral gene delivery may have non-
specifically altered the development of the mouse neurons.
Therefore, care was taken to subtract any changes observed
in the lentiviral-treated cells from the other datasets for all
analyses in an attempt to minimize the impact of this
potential artifact.Pathway analysis
NextBio analysis of the MSigDB pathways yielded a large
number of canonical pathways significantly enriched in
one or more treatment group. Three of these pathways
were significantly enriched in the luciferase versus blank
comparison but not in any other dataset. In addition, the
luciferase versus blank dataset yielded a number of pathways
in common with other shRNA datasets. These pathways
were considered nonspecific and excluded from further
analysis. After excluding these pathways, 256 canonical
pathways were significantly enriched in one or more treat-
ment groups. Many of these pathways were affected by more
than one condition; 26 pathways were significantly enriched
by 5 or more ASD shRNA datasets and the top 15 most
conserved are shown in Table 4. The most frequently
enriched pathway was the Neurotrophic tyrosine kinase
receptor type 1(TrkA) receptor pathway, in which all
datasets had a significant number of downregulated genes
except Pten, which had a significant number of upregu-
lated genes. Other pathways affected by multiple ASD
gene shRNA targets included signaling pathways related
to additional genes implicated in ASD, such as Neuregulin,
Mammalian Target Of Rapamycin (mTOR), and Reelin.
Figure 2 Hierachical clustering of intensity values from individual short-hairpin (sh)RNA knockdown experiments.
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pathway was significantly affected (that is, the number of
different shRNAs that altered that particular pathway); Up,
numbers of member genes altered in each pathway at least
1.5-fold broken out by positive fold-changes; Down,
numbers of member genes altered in each pathway at
least 1.5-fold broken out by negative fold-changes;
ASD, autism spectrum disorder; NFKB, Nuclear factor KB;
TrkA, Neurotrophic tyrosine kinase receptor type 1; PGC1A,
Peroxisome proliferator-activated receptor gamma coactiva-
tor 1-A ERBB3, Receptor tyrosine-protein kinase erbB-3.
GenSensor analysis of the Ingenuity pathways resulted in
114 canonical pathways which were significantly over-
represented in one or more of the ASD shRNA treatment
groups. The top fifteen most conserved pathways are
show in Table 5 (see Additional file 4: Table S3 for
the complete list). In the pathways found only in the
ASD shRNA treated samples, there are a number of
pathways related to neuronal signaling, in particularto cyclic AMP signaling. Thirteen of these pathways
were significantly enriched in the luciferase versus
blank comparison (yellow highlighted). These pathways
may indicate general effects of the shRNA delivery system
on the neuron cell culture. However, because GSS
does not consider the magnitude of gene expression
change, these results do not preclude real treatment-
related effects on these pathways above the background
levels induced by the lentivirus. Only two pathways were
found to be enriched solely in the luciferase versus blank
comparison.
Numbers are odds ranking of the pathways in each
shRNA experiment. All pathways were sorted by number
of shRNA experiments in which they appear (high to low)
followed by average ranking in experiments (low to high).
Italicized pathways were also enriched in the luciferase
control experiment. GNRH, gonadotrophin-releasing
hormone; THOP, Thimet oligopeptidase 1; NFAT, Nuclear
factor of activated T-cells.
Table 3 Autism spectrum disorder interactome genes significantly altered by three or more shRNA treatments
Gene Gene description Fold-change
Fmr1 Mecp2 Mef2a Mef2d Nlgn1 Nlgn3 Pten Shank3
Camk2a Calcium/calmodulin-dependent protein kinase II alpha 1.69 −2.00 −1.81 −1.65 −1.85 −1.68 −2.53 −1.68
Prmt1 Protein arginine N-methyltransferase 1 1.55 2.32 2.02 1.65 2.17 1.79 2.06
Cacna1c Calcium channel, voltage-dependent, L-type, alpha 1C subunit 1.68 1.75 1.69 1.90 1.64 1.67 2.23
Sh3gl3 SH3-domain GRB2-like 3 1.59 1.70 1.62 1.59 1.63 1.84 1.56
R3hdm1 R3H domain 1 (binds single-stranded nucleic acids) 2.40 −2.09 −1.63 1.92 −1.65 −1.88
Tgfb1i1 Transforming growth factor beta 1-induced transcript 1 −2.96 1.74 −3.19 2.48
Lims2 LIM and senescent cell antigen-like domains 2 2.43 1.75 3.80 1.90
Kif17 Kinesin family member 17 −2.01 −2.13 −2.36 −1.70
Nkd2 Naked cuticle 2 homolog (Drosophila) −1.78 −2.12 −1.83 −1.77
Capn3 Calpain 3 −1.65 1.53 2.98 −1.77
Nell1 NEL-like 1 (chicken) 2.23 −1.85 −1.58 1.64
PYCR1 Pyrroline-5-carboxylate reductase 1 −1.56 −2.81 −2.00 1.55
TBC1D9B TBC1 domain family, member 9B (with GRAM domain) 1.94 −2.08 1.57 1.50
Prr13 Proline-rich 13 −1.81 −1.77 −1.71 −1.82
STK32C Serine/threonine kinase 32C −1.89 −1.64 −1.69 −1.51
DLGAP2 Discs, large (Drosophila) homolog-associated protein 2 1.80 −1.60 −2.10
SOD1 Superoxide dismutase 1, soluble −1.64 −2.22 −1.69
Dlgap1 Discs, large (Drosophila) homolog-associated protein 1 1.91 −2.45 −1.86
MBD2 Methyl-CpG binding domain protein 2 −1.94 −1.58 −1.55
FBLN5 Fibulin 5 1.52 2.15 2.69
Sertad1 SERTA domain-containing 1 −1.67 −1.95 −1.69
Bhlhe40 Basic helix-loop-helix family, member e40 −2.28 −1.85 −1.74
Slit2 Slit homolog 2 (Drosophila) −1.68 −2.43 −2.09
Actn2 Actinin alpha 2 −2.64 −1.53 −1.65
Ube3a Ubiquitin protein ligase E3A −2.48 −1.52 −1.53
Slc13a3 Solute carrier family 13 (sodium-dependent dicarboxylate transporter),
member 3
2.32 1.56 −1.60
NOMO1 NODAL modulator 1 1.64 1.53 1.54
RALBP1 RalA binding protein 1 1.65 1.52 1.73
MYH10 Myosin, heavy chain 10, non-muscle −2.12 −1.78 −1.53
HMG20A High-mobility group 20A 1.68 1.59 1.76
BAIAP2 BAI1-associated protein 2 −1.51 −1.73 −1.55
Fxr1 Fragile X mental retardation gene 1, autosomal homolog 1.61 1.56 1.99
Lingo1 Leucine-rich repeat and Ig domain-containing 1 −1.56 −1.73 −1.57
Nup62 Nucleoporin 62 −1.54 −1.59 −1.70
Notch2 Notch gene homolog 2 (Drosophila) 1.69 1.52 −2.06
EML1 Echinoderm microtubule-associated protein-like 1 −1.64 1.72 −1.72
NECAB3 N-terminal EF-hand calcium-binding protein 3 −1.79 −1.52 −1.75
Tcf25 Transcription factor 25 (basic helix-loop-helix) −1.51 −1.69 −1.54
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CRE analysis yielded a large number of causal hypotheses
for each ASD shRNA treatment group. The rank order forthe hypotheses was as follows: Mecp2 (218) > Mef2d
(216) > Nlgn3 (174) >Mef2a (170) > Nlgn1 (151) > Shank3
(82) > Fmr1 (45) > Pten (12). The top fifteen hypotheses
Table 4 Canonical pathways in NextBio that were significantly enriched following ASD gene-targeted shRNA
constructs, but not affected by luciferase shRNA
ASD gene
count
Fmr1 Mecp2 Mef2a Mef2d Nlgn1 Nlgn3 Pten Shank3
Biogroup Up Down Up Down Up Down Up down Up Down Up Down Up Down Up Down
TrkA receptor 8 2 4 2 2 2 3 3 2
Erythropoietin-mediated neuroprotection through NFKB 7 3 2 3 3 1 2 1 3
PGC1A pathway 7 8 5 7 3 4 9 4
Long-term potentiation 7 8 18 5 15 3 16 6
Cell adhesion molecules (CAMs) 7 10 14 8 13 8 11 13 12 10
G2 and M phases 7 1 1 1 1 1 1 2 3
P53 HYPOXIA pathway 7 3 3 3 3 2 3 6
Biosynthesis of steroids 6 8 5 3 2 5 4
Arginine and proline metabolism 6 8 9 1 8 8 5
Antigen processing and presentation 6 9 3 6 3 10 4
BAD pathway 6 3 3 4 2 2 2
Neuroregulin receptor degredation protein-1 controls ERBB3 receptor
recycling
6 1 1 1 1 1 1
Eicosanoid synthesis 6 1 1 1 1 3 2
Phosphatidylinositol signaling system 5 10 17 6 11 10



















































Axonal guidance signaling 4 1 16 2 1 2 1 4 1 8 3.50
Molecular mechanisms of cancer 6 5 2 11 6 1 2 1 6 8 4.25
Breast cancer regulation by stathmin1 13 8 1 8 4 3 5 2 7 4.43
G-protein coupled receptor signaling 2 10 5 8 9 5 6.80
Protein kinase A signaling 6 18 2 14 3 5 8.60
Huntington’s disease signaling 23 1 37 22 3 5 17.20
Corticotropin-releasing hormone signaling 4 9 31 7 36 5 17.40
Calcium signaling 8 15 12 44 43 11 5 25.00
Amyotrophic lateral sclerosis signaling 4 15 66 41 7 5 26.60
Synaptic long-term potentiation 5 6 5 6 4 5.50
cAMP-mediated signaling 8 7 3 7 4 6.25
GNRH signaling 6 20 9 13 4 12.00
Neuropathic pain signaling in dorsal horn neurons 7 21 3 18 4 12.25
Neuroprotective role of THOP1 in Alzheimer’s disease 7 23 19 4 6 4 13.00



















Figure 3 Diverse set of ASD-associated genes produce similar pathway-level perturbations when knocked down. A total of 269
hypotheses were observed in at least three of the experiments and not in the blank. Only the hypotheses that were observed in at least 6 of the
treatment conditions are included in the figure (red squares indicate that the hypothesis was identified for that experimental condition).
Additional file 5: Table S4 list contains a full list of the 269 hypotheses. The notation (+) indicates the hypothesis is predicted to be upregulated,
and (−) indicates it is predicted to be downregulated. Names highlighted in orange are part of the molecular interaction network (Figure 4).
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http://www.molecularautism.com/content/4/1/45shared between the highest number of experiments is
shown in Figure 3 (See Additional file 5: Table S4 for the
complete list). There was no hypothesis that was seen in
all eight experimental conditions and not in the blank.
Looking at the experiments broadly, two groups emerge
based on the conservation. Mecp2, Mef2d, Nlgn3, Mef2a,
Nlgn1 and Shank3 share similar hypotheses and were
more dynamic, generating 3 to 5 times more hypotheses.
In contrast, the same hypotheses are not seen being impli-
cated for the Fmr1 and Pten experiments, with the latter
experiment appearing quite different than the rest. The
predicted hypotheses are overwhelmingly downregulated,
with 86% (230 of 268) with the respective order of contri-
bution being 87% (Mecp2), 89% (Mef2d), 84% (Nlgn3), 86%
(Mef2a), 87% (Mef2a), 76% (Nlgn1), and 79% (Fmr1); Pten
again is the exception with only 58%. Figure 4 is a
composite of the most conserved hypotheses gen-
erated by CRE for the seven concordant treatment
groups. Recurring hypotheses are highlighted with cir-
cles. The central hubs of the network are cyclic AMP
and the extracellular signal-regulated kinase (ERK)1/2
family, which are directly connected to seven and
eight primary hypotheses respectively.Confirmation of BDNF protein response
Given that multiple hypotheses predicted from multiple
target-knockdown datasets converge on Bdnf, regulation
of Bdnf could play a central role in ASD pathobiology.
In order to confirm that these predicted changes in BDNF
were accurate and that the transcriptional changes measured
translated to the protein level, the two shRNA conditions
in which Bdnf mRNA was most robustly altered
(Fmr1 and Mecp2) were evaluated for impacts on
BDNF protein. Neurons were treated in the same
manner as for the microarray study, and lysates were
harvested and analyzed by ELISA for BDNF. As predicted
by mRNA levels, the luciferase shRNA construct alone
significantly lowered BDNF (P-value <0.05) (Figure 5).Mecp2
shRNA further reduced BDNF levels, while Fmr1 shRNA
significantly increased BDNF levels relative to luciferase
shRNA (P-value <0.05).
Discussion
ASD is a neurological disorder with a strong genetic
component that has been linked to a number of gene
defects. These genes have a broad range of activities,
ranging from membrane receptors and scaffold proteins
8/4-MeCP2, Mef2a, Mef2d, Nlgn1
9/3-MeCP2, Mef2a, Mef2d
1/7-MeCP2, Mef2a, Mef2d, 
Nlgn1, Nlgn3, Shank3, Fmr1
4/6-MeCP2, Mef2a, Mef2d, Nlgn1, Nlgn3, Shank3
11/3-MeCP2, Mef2d, Nlgn1
Figure 4 Multiple causal reasoning engine (CRE)-predicted hypotheses collapse into a molecular interaction network. The edges of the
connections represent the information linking the nodes, for example, a PubMed reference for the interaction. The hypotheses are colored based
on the direction of regulation: blue nodes are predicted down, whereas yellow are predicted up. Circled regions indicate significant hypotheses
seen in different short-hairpin (sh)RNA experiments: red - Myocyte enhancer factor (Mef)2d, Methyl-CpG binding protein (Mecp)-2, Neuroligin (Nlgn1);
blue - Mef2a, Mef2d, Mecp2; green - Mef2a Mef2d, Mecp2, Ngln1; light blue - Mecp2, Mef2a, Mef2d, Nlgn1, Nlgn3, SH3 and multiple ankyrin repeat
domains (Shank)3; black - Mecp2, Mef2a, Mef2d, Nlgn1, Nlgn3, Shank3, Fragile X mental retardation (Fmr)1 (IL2-hypothesis).
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Despite this diversity, ASD patients manifest with similar
behavioral and neuronal phenotypes, albeit with different
severities. This commonality of neurological phenotype
suggests that the genetic defects may act through a limited
set of pathways. In this report, we employed shRNA
knockdown of eight ASD relevant genes in neuronal
culture to explore the downstream effects and identify
common pathways or transcriptional signatures.
Following microarray analysis of all samples, we performed
cluster analysis on the intensity values. As expected, samples
clustered by treatment group, demonstrating an overall
consistency and quality of the knockdown experiment and
subsequent gene expression quantitation. It also illustrates
the distinctiveness of the downstream expression effects of
knockdown of individual genes. Knockdown of Pten and
Mecp2 had the most dramatic effects on gene expression.
Given Pten’s broad role in numerous cellular processes and
Mecp2’s role as a transcription factor, these results were not
unexpected. For example, mutations in Pten have been
linked not only to ASD but also cancer and diabetes [53,54].
Fragile X mental retardation protein (FMRP), the protein
product of Fmr1, has been shown to interact with a larger
number of target proteins in relation to dendritic control of
translation. A list of FMRP target proteins showed significant
enrichment in the transcriptional profiles of shRNA for not
only Fmr1, but also Mecp2, Pten, Shank3, Nlgn1 and Nlgn3
[25]. We further compared the genes affected in one or more
knockdown experiments to a list of ASD interactome genes[20]. This comparison indicated that knockdown of the eight
ASD genes resulted in changes to a significant number of
ASD interactome genes and the genes affected by the lucifer-
ase shRNA condition had little overlap with the ASD genes
(Table 3). This control comparison is important, as other
groups have reported nonspecific adverse effects of other
shRNA and siRNA constructs [55,56]. The luciferase shRNA
versus untransduced comparison yielded almost 1,000 differ-
entially expressed transcripts, with an impact on BDNF mea-
sured at the protein level. Thus, by identifying the changes
in the luciferase shRNA versus untransduced experi-
ments and subtracting those, the subsequent pathway
analyses could focus on pathways that were specifically
targeted by knockdown of the ASD-relevant genes and
not identify artifacts of the transduction.
We next analyzed the gene lists from the shRNA
experiments by two pathway analysis approaches to obtain
different perspectives on the data. The most prominent
pathways revealed through analysis with NextBio were a
number of pathways related to neurologic signaling and
function (Table 4). Secondarily, NextBio indicated that
several pathways involved general cellular metabolism and
growth were also affected. One prominent pathway,
the Peroxisome proliferator-activated receptor gamma
coactivator 1-A (PGC1A) pathway, is based on the MSigDB’s
version of BioCarta’s pathway and contains Mef2A and
several calcium-dependent kinases, which show gene
expression changes in all shRNA experiments. One aspect
of the NextBio analysis is that directionality of change
Figure 5 Measurement of BDNF protein levels in 14-days-in vitro mouse cortical neurons following transduction with short-hairpin (sh)
RNA constructs for luciferase (non-mammalian control), Fragile X mental retardation (Fmr1), Methyl-CpG binding protein (Mecp2) or
non-transduced neurons (blank). Values for mRNA and protein as % of luciferase control shRNA are shown in the table on the right
(n = 12 per group).
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majority of the pathways are downregulated with ASD
shRNA knockdown, suggesting that the genes we chose
for this work are needed for the expression of these
pathways and thereby their activity. Pathway analysis
with GenSensor also identified a number of pathways
related to neuronal signaling and function (Table 5).
As with the NextBio analysis, several growth and metabolism
pathways were also affected.
During an examination of the individual pathways
identified by the two pathway analysis methods, we
noted a recurring involvement of the mitogen-activated
protein kinase kinase (MEK)/ERK signaling pathway.
These effects would occur either directly through a
kinase signaling cascade (downstream of BDNF/TRK) or
via cAMP (as in the case of the dopamine and serotonin
G-protein coupled receptors). To further investigate this
potential commonality, we employed CRE analysis to
identify potential underlying mechanisms (CRE hypotheses)
in the shRNA datasets. Unlike pathway analysis, which
identifies pathways with altered gene expression, CRE
analysis predicts potential mechanisms behind gene
changes based on the concordance of the number of
genes that change expression, and the directionality
of that change [47]. The results of CRE analysis are
interlinked hypotheses of potential driving mechanisms or
experimental treatments that exhibit similar gene changes.It is interesting that three of the eight most conserved
hypotheses have a biological function suggestive of growth
and/or immune function, suggesting similar driving
mechanisms (Figure 3). Likewise, there are highly conserved
hypotheses involved with neurogenesis, synaptic activity
and differentiation, as expected, although not mutually
exclusive. Choosing the Mef2d experiment as a representa-
tive of the six most conserved shRNA treatments, the top
ranking clusters can be connected as a molecular inter-
action map with (Figure 4), cyclic AMP and ERK serving as
dual hubs of the network directly connecting seven and
eight related hypotheses respectively. Three of the
experiments, Mecp2, Mef2d, and Nlgn1, shared 11 of the
12 hypotheses in the network. As more experiments are
included, the shared number of hypotheses decreases, for
example, the light blue grouping of six experiments
including Shank3 is based on four hypotheses.
In addition to this work, other work directly or indirectly
supports a role for ERK signaling in the development of
ASD. For example, maternal use of one of several different
classes of drugs relevant to ERK modulation has been
reported to increase the risk of having children born with
ASD [57]. Cocaine use during pregnancy has been
reported to increase the rate of autism by 11%. Cocaine
use has also been shown to alter dopamine-induced
phosphorylation of ERK via cAMP [58,59]. Recently,
Hoffmann et al. showed that chronic cocaine use in rats
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cocaine use might thereby attenuate ERK signaling in the
fetus. Similarly, mothers taking valproic acid, an inhibitor of
gamma-aminobutyric acid (GABA) function, have been
demonstrated to have an increased risk of have children
with autism [61]. As with cocaine, valproic acid acti-
vates ERK signaling [62]. Zou et al. demonstrated that
RAS/RAF/ERK1/2 signaling was upregulated in the
brains of the BTBR mouse model of autism [63]. Recently,
the upregulation of this pathway (and of ERK5) has been
shown to occur in the brains of autistic subjects [64].
Although misregulation of ERK does appear to be a
common feature of ASD, the observed directionality of that
misregulation has been contradictory. In the case of Rett
syndrome, ERK signaling through the BDNF pathway in
particular is reduced. BDNF levels are reduced inMecp2-null
mice, and exogenous BDNF has been shown to rescue
deficits due to Mecp2 deficiency [7,9]. In human Rett
syndrome patients, a Val/Met polymorphism in BDNF has
been associated with disease severity [18]. In the present
study, Mecp2 shRNA produced a significant reduction in
Bdnf at both the mRNA and protein level, both of which
were inversely affected by Fmr1 knockout. Given the diverse
functions of BDNF in neurons, it would be interesting
to determine in follow-up studies whether inverse functional
outcomes may be observed with these treatments.
Based on the experimental data presented here and
previously existing data, we have put together a pathway
model to show that the transcriptional regulation exerted
by a diverse set of ASD-associated genes converges on
ERK signaling. A central role for ERK signaling would
explain many of the features associated with ASD. Early
work on the ERK proteins described these as microtubule-
associated protein 2 kinases, and were shown to phosphoryl-
ate MAP2 kinases, proteins known to be involved in
neuronal architecture [65-67]. Later work demonstrated
that ERK plays a critical role in microtubule formation and
thereby to axon/dendrite formation [68,69]. A review article
by Hoogenraad and Akhmanova has summarized the critic-
ality of microtubules in synaptic plasticity [70]. Mutations
that lead to altered ERK activity would then be expected to
have alterations in axon extension and/or retraction and
thereby, synaptic plasticity. Mazzucchelli et al. found that
ERK1-knockout mice exhibit enhanced synaptic plasticity,
most likely through the compensatory activation of ERK2
[71]. Voineagu et al. recently reported that the expression
differences between the temporal and frontal lobes are
significantly attenuated in individuals with autism [22].
They further suggested that this lack of differentiation is
the mechanism behind the lack of long-range axonal
connections and the decreased myelin thickness in autistic
prefrontal lobes as reported by Zikopoulos and Barbas
[21,22]. In some instances altered ERK activity could inter-
fere with neuroglia wrapping of neuritis to form themyelin sheath. Newbern et al. recently reported that
ablation of ERK1/2 in Schwann cell precursors resulted in
hypomyelination of axons [72].
Conclusions
A large number of genetic mutations and CNVs have
been linked to ASD. The implicated genes span a variety
of functions and pathways [25,35]. Despite this diversity,
defects in neuronal plasticity and dendrite morphology
are commonly associated with this disease. In this report, we
utilized shRNA knockdown of eight ASD-associated genes
to examine downstream transcriptional alterations and to
look for pathway-level commonalities. An underlying as-
sumption is that dysregulation of these genes in primary
mouse cortical neurons produce transcriptional alterations
robust enough to be detected in lysates of these mixed
cultures. As it is difficult in such an experiment to identify a
single causal gene, analyzing changes at the pathway level
mitigates the reliance on just one or two genes. Pathway ana-
lysis by two different approaches both identified alterations
in a number of conserved neuronal signaling pathways.
Detailed examination of those pathways emphasized alter-
ations to the cAMP and ERK signaling pathways. These
pathways would be good starting points for further func-
tional characterization of common downstream neuronal
phenotypes following known-down of ASD-associated genes.
For example, cAMP reporter assays and phosphopro-
teomic analysis of ERK pathway regulation would be
informative in searching for common intervention
points that might reverse the phenotypes caused by
the ASD gene disruption. The prospect that multiple
genes tied to a single disorder converge on a com-
mon set of pathways provides hope that therapeutics
can be developed that will be efficacious in a patient
population with a heterogeneous genetic background.
Additional files
Additional file 1: Figure S1. Western blot analysis of protein knockdown.
Additional file 2: Table S1. Full gene expression data.
Additional file 3: Table S2. Comparison of individual gene expression
changes between knockdown datasets. Genes that had fold-changes >1.5
versus control with a P-value <0.5 were compared between experiments for
overlap. The number of genes found in both knockdown experiments for
any combination is shown on the table.
Additional file 4: Table S3. Gene set enrichment analysis utilizing
Ingenuity pathways.
Additional file 5: Table S4. A comparison of common causal reasoning
engine (CRE) hypotheses from the nine experiments A total of 269
hypotheses were observed in at least three of the experiments and not in
the blank. The notation (+) indicates the hypothesis is predicted to be
upregulated, and (−) predicted it to be downregulated. Names highlighted in
orange are part of the molecular interaction network (Figure 4). An observed
hypothesis (indicated by a red box) satisfies the following filters: correctness
P-value <0.05, enrichment P-value <0.05, minimum number of correctly
explained gene expression changes ≥3, percent correctly explained gene
expression changes ≥60%, ranking score <100.
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